ArticleThe Journal of clinical endocrinology and metabolism2012
Circulating osteogenic precursor cells in type 2 diabetes mellitus.
Article in The Journal of clinical endocrinology and metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03814811 (Circulating Osteocalcin-positive Cells as a Cell-Based Biomarker of Breast Cancer Bone Metastasis Progression), which is not on this map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Circulating Osteocalcin-positive Cells as a Cell-Based Biomarker of Breast Cancer Bone Metastasis Progression
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.
- [Diagnosis and management of patients with diabetes and co-existing osteoporosis (Update 2023) : Common guideline of the Austrian Society for Bone and Mineral Research and the Austrian Diabetes Society].Wiener klinische Wochenschrift · 2023Guideline
- Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.Frontiers in endocrinology · 2025Trial
- Circulating osteogenic progenitors and osteoclast precursors are associated with long-term glycemic control, sex steroids, and visceral adipose tissue in men with type 2 diabetes mellitus.Frontiers in endocrinology · 2022Trial
- Hemoglobin A1c Threshold for Reduction in Bone Turnover in Men With Type 2 Diabetes Mellitus.Frontiers in endocrinology · 2021Trial
- Effects of a 3-month weight-bearing and resistance exercise training on circulating osteogenic cells and bone formation markers in postmenopausal women with low bone mass.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Trial
- Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus.Endocrine · 2015Trial
- [Diagnosis and management of diabetes and co-existing osteoporosis (Update 2026)].Wiener klinische Wochenschrift · 2026Review
- A novel computed tomography-based algorithm for the quantitative identification of lumbar spine-localized trabecular bone loss in patients with type 2 diabetes mellitus.Quantitative imaging in medicine and surgery · 2026Article
- Intermittent fasting triggers interorgan communication to improve the progression of diabetic osteoporosis.Gut microbes · 2025Article
- New Aspects of the Pathophysiology of Diabetic Bone Fragility - Type 2 Diabetes Mellitus as a Disease of Accelerated Aging.Current osteoporosis reports · 2025Review
- Focal bone defects in type 2 diabetes mellitus patients with acute hip fractures.Quantitative imaging in medicine and surgery · 2025Article
- Pathophysiology of Bone Fragility in Type 2 Diabetes Mellitus.Current osteoporosis reports · 2025Review
- Review
- The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease.Nature reviews. Endocrinology · 2025Review
- Correlation Between Blood Glucose Fluctuations and Osteoporosis in Type 2 Diabetes Mellitus.International journal of endocrinology · 2025Review
- Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review.Drug design, development and therapy · 2025Review
- Article
- Sclerostin as a new target of diabetes-induced osteoporosis.Frontiers in endocrinology · 2024Review
- A Model of Immediate Implant Placement to Evaluate Early Osseointegration in 129/Sv Diabetic Mice.The International journal of oral & maxillofacial implants · 2023Article
- Biochemical Markers of Bone Fragility in Patients with DiabetesThe Journal of clinical endocrinology and metabolism · 2023Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextType 2 diabetes mellitus (T2D) is associated with an increased risk of fractures and low bone formation. However, the mechanism for the low bone formation is not well understood. Recently, circulating osteogenic precursor (COP) cells, which contribute to bone formation, have been characterized in the peripheral circulation.
objectiveOur objective was to characterize the number and maturity of COP cells in T2D. PATIENTS, DESIGN, AND
settingEighteen postmenopausal women with T2D and 27 controls participated in this cross-sectional study at a clinical research center.
main outcome measuresCOP cells were characterized using flow cytometry and antibodies against osteocalcin (OCN) and early stem cell markers. Histomorphometric (n = 9) and molecular (n=14) indices of bone turnover and oxidative stress were also measured.
resultsThe percentage of OCN(+) cells in peripheral blood mononuclear cells was lower in T2D (0.8 ± 0.2 vs. 1.6 ± 0.4%; P < 0.0001), whereas the percentage of OCN(+) cells coexpressing the early marker CD146 was increased (OCN(+)/CD146(+): 33.3 ± 7 vs. 12.0 ± 4%; P < 0.0001). Reduced histomorphometric indices of bone formation were observed in T2D subjects, including mineralizing surface (2.65 ± 1.9 vs. 7.58 ± 2.4%, P = 0.02), bone formation rate (0.01 ± 0.1 vs. 0.05 ±0.2 μm(3)/um(2) · d, P = 0.02), and osteoblast surface (1.23 ±0.9 vs. 4.60 ± 2.5%, P = 0.03). T2D subjects also had reduced molecular expression of the osteoblast regulator gene Runx2 but increased expression of the oxidative stress markers p66(Shc) and SOD2.
conclusionsCirculating OCN(+) cells were decreased in T2D, whereas OCN(+)/CD146(+) cells were increased. Histomorphometric indices of bone formation were decreased in T2D, as was molecular expression of osteoblastic activity. Stimulation of bone formation may have beneficial therapeutic skeletal consequences in T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.